PT - JOURNAL ARTICLE AU - Anna Jones AU - Kay Rodgers AU - Debbie Jeffrey AU - Waqas I Ali AU - HJN Andreyev TI - Nivolumab-induced exocrine pancreatic insufficiency AID - 10.1136/flgastro-2021-102013 DP - 2021 Dec 20 TA - Frontline Gastroenterology PG - flgastro-2021-102013 4099 - http://fg.bmj.com/content/early/2021/12/19/flgastro-2021-102013.short 4100 - http://fg.bmj.com/content/early/2021/12/19/flgastro-2021-102013.full AB - Immune checkpoint inhibition is the standard-of-care for many advanced cancers. Side effects of therapy may prevent optimal treatment of the cancer. Management of side effects is dominated by recommendations derived from oncological, not gastroenterological practice. We report a patient who developed pancreatic insufficiency during checkpoint inhibitor therapy with a programmed cell death receptor 1 inhibitor, nivolumab, which if not diagnosed would have prevented ongoing treatment. This is a problem which affects approximately 1 in 100 patients treated with this agent but is rarely recognised. Gastroenterologists need to be aware of the spectrum of gastrointestinal disorders which occur after immunotherapy to treat cancer.